Super-resolution microscopy showed sunitinib disrupts key cellular structures. Solid-state NMR is revealing atomic-level structures of formulated drugs, supported by a new NSF-funded project.
The FDA granted Breakthrough Therapy Designation to bezuclastinib plus sunitinib for previously treated GIST. The PEAK trial showed median progression-free survival of 16.5 months versus 9.2 months for sunitinib alone.
Cogent Biosciences is preparing parallel FDA submissions for bezuclastinib across three indications following positive pivotal trial results, with potential launches beginning in late 2026 and full commercialization expected by early 2027.
| NCT ID | Title | Status | Phase |
|---|---|---|---|
| NCT07218926 |
A Study of IDRX-42 (GSK6042981) Versus (vs) Sunitinib in Participants With Gastrointestinal Stromal Tumors After Imatinib Therapy |
RECRUITING | PHASE3 |
| NCT06948955 |
Expanded Access to Bezuclastinib to be Coadministered With Sunitinib for Patients With Gastrointestinal Stromal Tumors |
AVAILABLE | |
| NCT06390826 |
Testing Sunitinib as Potentially Targeted Treatment in Cancers With cKIT Genetic Changes (MATCH - Subprotocol V) |
ACTIVE_NOT_RECRUITING | PHASE2 |
| NCT05773274 |
Comparing Retreatment of 177Lu-DOTATATE PRRT Versus the Usual Treatment in Patients With Metastatic Unresectable Gastroenteropancreatic Neuroendocrine Tumors, NET RETREAT Trial |
RECRUITING | PHASE2 |
| NCT05208047 |
(Peak) A Phase 3 Randomized Trial of CGT9486+Sunitinib vs. Sunitinib in Subjects With Gastrointestinal Stromal Tumors |
RECRUITING | PHASE3 |
| NCT03900793 |
Losartan + Sunitinib in Treatment of Osteosarcoma |
RECRUITING | PHASE1 |
| NCT03899155 |
Pan Tumor Rollover Study |
RECRUITING | PHASE2 |
| NCT03768063 |
A Study in Patients Previously Enrolled in a Genentech and/or F. Hoffmann-La Roche Ltd Sponsored Atezolizumab Study |
ACTIVE_NOT_RECRUITING | PHASE3 |
| NCT03091192 |
Savolitinib vs. Sunitinib in MET-driven PRCC. |
ACTIVE_NOT_RECRUITING | PHASE3 |
| NCT02848768 |
Validation of a Predictive Nomogram of Response or Resistance to Targeted Therapies in Metastatic Clear Cell Renal Cell Carcinoma |
COMPLETED |
